Rosiglitazone and Its Effects on Gastric Cancer Cells
Author Information
Author(s): He Qing, Pang Ruiping, Song Xin, Chen Jie, Chen Huixin, Chen Baili, Hu Pinjin, Chen Minhu
Primary Institution: The First Affiliated Hospital, Sun Yat-Sen University
Hypothesis
The study investigates how rosiglitazone affects the growth, invasiveness, and angiogenesis of SGC-7901 gastric cancer cells.
Conclusion
Rosiglitazone inhibits the growth and invasiveness of SGC-7901 gastric cancer cells and angiogenesis in vitro through both PPARγ-dependent and independent mechanisms.
Supporting Evidence
- Rosiglitazone inhibited SGC-7901 gastric cancer cell growth in a dose-dependent manner.
- Treatment with the PPARγ antagonist GW9662 reversed the effects of rosiglitazone on cell viability.
- RGZ treatment increased the number of cells in the G1 phase and decreased those in the S phase.
- RGZ significantly reduced cell migration and invasiveness compared to control.
- RGZ suppressed the formation of tube-like structures in HUVECs in a dose-dependent manner.
Takeaway
Rosiglitazone is a drug that can help stop stomach cancer cells from growing and spreading, and it can also prevent new blood vessels from forming in tumors.
Methodology
The study used cell culture, RT-PCR, Western blotting, ELISA, and various assays to assess cell viability, migration, invasion, and angiogenesis.
Limitations
The study primarily focuses on in vitro results, which may not fully represent in vivo conditions.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website